Although much less is known about BCR-ABL-independent resistance, a recent genetic study has shown that it can vary between individuals, often suggesting re-activation of signaling pathways involved in CML pathogenesis (15). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.